Abstract | BACKGROUND AND AIMS: METHODS: We evaluated vitamin E supplementation as therapy for chronic hepatitis B in a pilot study including 32 patients. Patients were randomly allocated to receive vitamin E at the dose of 300 mg twice daily for 3 months (15 patients) or no treatment (17 patients). They were seen monthly during the first 3 months and thereafter quarterly for additional 12 months. RESULTS: The two groups were comparable at enrollment. At the end of the study period, alanine aminotransferase (ALT) normalization was observed in 7 (47%) patients in vitamin E group and only in 1 (6%) of the controls (P=0.011); HBV- DNA negativization was observed in 8 (53%) patients in the vitamin E group as compared to 3 (18%) in the control group, respectively (P=0.039). A complete response (normal ALT and negative HBV- DNA) was obtained in 7 (47%) patients taking vitamin E and in none of the controls (P=0.0019). CONCLUSION:
|
Authors | P Andreone, S Fiorino, C Cursaro, A Gramenzi, M Margotti, L Di Giammarino, M Biselli, R Miniero, G Gasbarrini, M Bernardi |
Journal | Antiviral research
(Antiviral Res)
Vol. 49
Issue 2
Pg. 75-81
(Feb 2001)
ISSN: 0166-3542 [Print] Netherlands |
PMID | 11248360
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- DNA, Viral
- Vitamin E
- Alanine Transaminase
|
Topics |
- Adult
- Alanine Transaminase
(blood)
- DNA, Viral
(blood)
- Female
- Hepatitis B virus
(isolation & purification, physiology)
- Hepatitis B, Chronic
(drug therapy, virology)
- Humans
- Male
- Middle Aged
- Pilot Projects
- Treatment Outcome
- Vitamin E
(therapeutic use)
|